Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity

Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the potential for ivermectin to be repurposed as an...

Descripción completa

Detalles Bibliográficos
Autores principales: Eastman, Richard T., Rusinova, Radda, Herold, Karl F., Huang, Xi-Ping, Dranchak, Patricia, Voss, Ty C., Rana, Sandeep, Shrimp, Jonathan H., White, Alex D., Hemmings, Hugh C., Roth, Bryan L., Inglese, James, Andersen, Olaf S., Dahlin, Jayme L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634736/
https://www.ncbi.nlm.nih.gov/pubmed/37961094
http://dx.doi.org/10.1101/2023.10.23.563088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634736/
https://www.ncbi.nlm.nih.gov/pubmed/37961094
http://dx.doi.org/10.1101/2023.10.23.563088

Ejemplares similares